Bullish Biotech Bets After Positive Attention

Biotechnology ETFs have been getting plenty of positive attention in recent weeks, a trend that certainly extends to the SPDR S&P Biotech ETF (XBI). The equal-weight XBI, the second-largest biotech ETF by assets, is up more than 40% year-to-date, making it one of this year’s best-performing non-leveraged ETFs. There are plenty of fundamental accolades [...] Read more on ETFtrends.com >

Advertisement